News

ACC, Statin Intolerance App, statin therapy, muscle symptoms, pain

The American College of Cardiology (ACC) Statin Intolerance App is now available to help guide clinicians through the process of managing and treating patients who report muscle symptoms while on...

cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent

The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary...

VHA, dabigatran, patient adherence, JAMA, Mintu Turakhia

Atrial fibrillation patients on the anticoagulant dabigatran were more likely to adhere to the medication with appropriate patient selection and pharmacist-led monitoring, according to a study in...

Merck, IMPROVE-IT, results, New England Journal of Medicine, NEJM, Vytorin

Merck announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with Vytorin (ezetimibe and...

Patients who received a bare metal coronary stent did not display significant differences in rates of adverse events with an additional 18 months of dual antiplatelet therapy rather than placebo,...

Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results

AstraZeneca announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial investigating Brilinta (ticagrelor) tablets plus low dose aspirin, at the American College of...

Researchers from the University of Chicago and Stanford University combed through scientific literature on the pharmacogenomics of 71 leading cardiovascular drugs to help physicians better...

rivaroxaban, Xarelto, VENTURE-AF, VKA, atrial fibrillation, Heart Rhythm 2015

Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the VENTURE-AF trial. The study explored the potential of once-daily Xarelto (rivaroxaban) as...

antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI

A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive...

cilostazol, DAPT, bridge therapy, surgery, bleeding risk, SCAI

Patients with a high-risk paclitaxel drug-eluting stent given the shorter-acting antiplatelet drug cilostazol prior to a surgical procedure safely transitioned off of dual antiplatelet therapy (...

PROMETHEUS, prasugrel, clopidogrel, heart disease, bleeding, SCAI

Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneous coronary intervention (PCI) compared to clopidogrel, according to a new study. Results...

A new study reports that antiplatelet drug ticagrelor (Brilinta) works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary syndrome (ACS) than...

blood pressure, LDL, medication therapy, coronary plaque, SCAI

Combining statins for low-density lipoprotein (LDL) and calcium channel antagonists for blood pressure reduces harmful coronary plaque, according to a study presented at the Society of...

heart stent, OAP therapy, ACS, patients, PCNA, SCAI, medication, prescribed

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart...

One life-threatening complication of lung cancer surgery is the formation of blood clots in the lungs (also called pulmonary embolism, PE) or in the legs (also known as deep vein thrombosis, DVT...

Brilinta, AstraZeneca, FDA, sNDA, PEGASUS-TIMI 54, new indication

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for Brilinta (ticagrelor) tablets for...

The Medicines Company, cangrelor, FDA advisory committee, approval

The Medicines Company announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9 - 2 with one abstention to recommend approval of...

ivabradine (Corlanor)

The U.S. Food and Drug Administration (FDA) approved Amgen’s ivabradine (Corlanor) to reduce hospitalization from worsening heart failure.

A study including more than 20,000 adults in China found combined use of the hypertension medication enalapril and folic acid significantly reduced the risk of first stroke. All of the patients...

The Medicines Company announced that the European Commission has granted marketing authorization for two acute care products – Kengrexal (cangrelor) and Raplixa (sealant powder). These approvals...